AdvisorShares Psychedelics ETF (PSIL)
ARCA ARCA Primary Summary
PSIL Chart
Groovy: Psychedelics ETF PSIL a Top-5 Active ETF YTD
2025 is drawing to a close, and investors have plenty to look back on. Active ETF performance and proliferation was once again an important theme, and as the category matures, its standout performers have diversified.
This Psychedelics ETF Has Investors Going Crazy (In a Good Way)
When it comes to curing common ailments, the majority of doctors won't be prescribing things like LSD, mescaline, PCP, or psilocybin (mushrooms) anytime soon. But these are examples of a growing billion-dollar psychedelic drugs industry that's poised for even more growth.
5 ETFs That Beat the Market in the First Half of 2025
SGDM, SLVP, SHLD, URA and PSIL top the charts in the first half of 2025, defying market turmoil and riding sector-specific surges.
AdvisorShares Psychedelics ETF Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JA Jeff Ameen Spire Wealth Management | 2,000 | $21,969.04 | $39,560 | $17,590.96 | 80.07% |
| BB Brian Baylis Bell Investment Advisors Inc. | 75 | $911.71 | $1,454.25 | $542.54 | 59.51% |
 Christopher C. Powers Farther Finance Advisors, LLC | 756 | $8,517 | $14,658.84 | $6,141.84 | 72.11% |
AdvisorShares Psychedelics ETF (PSIL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has AdvisorShares Psychedelics ETF ever had a stock split?
AdvisorShares Psychedelics ETF Profile
| ARCA Exchange | US Country |
Overview
The fund represents an actively managed Exchange-Traded Fund (ETF) with a focus on investments in the psychedelic drugs sector. Its primary objective is to invest in companies that either generate at least 50% of their revenue from, or allocate the same proportion of their assets to, psychedelic drugs and their derivatives. Furthermore, to meet its investment goals, the fund commits at least 80% of its net assets (including any borrowings for investment purposes) towards securities of such companies. This ETF is particularly interested in life sciences companies that are pioneers in psychedelic medicines, although it also embraces other companies involved in the psychedelics business. It's important to note that the fund is non-diversified, meaning it might concentrate its investments more heavily in fewer companies, making it more susceptible to the risks associated with those companies.
Products and Services
- Investment in Psychedelic Drug Companies: The fund focuses on engaging with companies that derive at least 50% of their net revenue from or devote an equivalent percentage of their assets to psychedelic drugs. This includes investments in a spectrum of life sciences firms that are leading the way in developing psychedelic medicines. This strategy targets the burgeoning sector of psychedelic research, which holds potential for significant advancements in mental health treatments.
- Securities of Psychedelic Medicine Companies: By primarily investing in publicly listed companies engaged in the research, development, and distribution of psychedelic medicines, the fund provides investors with exposure to this innovative and evolving industry. This not only includes companies directly involved in psychedelics but also those contributing to the business of psychedelics in related ways.
